Vaccinex is committed to innovation in the way we approach drug discovery and development.

Vaccinex is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and other targeted biological therapies. A Vaccinex antibody product is currently in clinical trials for immunotherapy of cancer and to prevent or delay the onset of neurodegenerative Huntington’s disease.

Learn more about our company




Vaccinex has discovered and developed an immune-modulating, anti-semaphorin 4D (SEMA4D) antibody that has been shown in preclinical studies to regulate the infiltration of immune cells into the tumor microenvironement. Specifically, anti-SEMA4D induces an increase in tumor-specific cytotoxic T cells and a change in the balance of tumoricidal and regulatory macrophage toward a pro-inflammatory, anti-tumorigenic response.

Learn more about VX15 for Immuno-Oncology




Huntington’s disease (HD) is a chronic inflammatory disease of the central nervous system characterized by nerve cell death. Given the debilitating nature of the motor, cognitive and behavioral dysfunction associated with HD, there exists a significant need to identify novel therapeutic targets and strategies that safely and effectively prevent or delay the onset of this genetically determined disease.

Learn more about VX15 for Neurology

technology platform


ActivMAb® is Vaccinex’s antibody discovery and optimization platform. ActivMAb® combines the advantages of both viral panning and cell sorting to enable the efficient identification of high-affinity, fully human antibodies from antibody libraries expressed in mammalian cells. A fusion protein of immunoglobulin heavy chain with a vaccinia membrane protein (Ig-VMP) has been developed that enables efficient expression on the surface of vaccinia virus, an enveloped mammalian virus, as well as on the surface of the infected cell.

Learn more about ActivMAb®